---
company: LifeStance Health Group, Inc.
ticker: LFST
form: 8-K
filed: 2026-11-05
accepted: 2026-11-05T00:56:41+00:00
accession: 0001193125-26-447943
source: https://www.sec.gov/Archives/edgar/data/1845257/000119312526447943/
---

# LifeStance Health Group (LFST) Q3 2026 earnings

## Header

- Company: LifeStance Health Group, Inc.
- Reported: 2026-11-04 19:56 AMC ET
- Source: 8-K only — accession 0001193125-26-447943, Item 2.02 + Exhibit 99.1
- Verdict: Revenue and Adjusted EBITDA grew 25% and 70% respectively, with Center Margin rising 38% to 35.4% of revenue.

## Headline numbers

| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $455.9 million | +25.0% | +4.7% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.06 | +$0.06 | +$0.00 | Ex. 99.1, income statement |
| EPS (adjusted) | NM | — | — | Ex. 99.1, income statement |
| Net income | $22.4 million | +$21.3 million | -$1.2 million | Ex. 99.1, income statement |
| Adj. EBITDA | $68.4 million | +28.2 million | +2.4 million | Ex. 99.1, income statement |
| Adj. EBITDA margin | 15.0% | +3.9 pp | -0.2 pp | Ex. 99.1, income statement |

## Revenue breakdown

not stated in the 8-K

## Margins and costs

- Gross margin: not stated in the 8-K
- Operating expenses: $422.8 million (+18.6% YoY)
- One-offs in the quarter: Loss on remeasurement of contingent consideration: $2.3 million; Transaction costs: $0.5 million; Executive transition costs: $0.0 million; Litigation costs: $0.0 million; Strategic initiatives: $1.7 million; Real estate optimization and restructuring charges: $0.0 million
- Effective tax rate: 22.4% (prior-year 76.4%, year-to-date 19.3%)
- Non-GAAP bridge: Adds back interest expense, depreciation and amortization, income tax provision, loss on remeasurement of contingent consideration, stock-based compensation, loss on disposal of assets, transaction costs, executive transition costs, litigation costs, strategic initiatives, real estate optimization and restructuring charges, and amortization of cloud-based software implementation costs.

## KPIs

| Metric | Actual | Prior quarter | Prior year | Change |
|---|---:|---:|---:|---:|
| Clinician base | 8,863 | 8,542 | 7,992 | +321 net increase |
| Visit volumes | 2.7 million | 2.6 million | 2.3 million | +17% YoY |
| Center Margin | $161.4 million | $153.0 million | $116.6 million | +38% YoY |
| Free Cash Flow | $22.4 million | $87.9 million | $6.2 million | +260% YoY |

## Guidance

| Metric | Guide | Prior guide | Change |
|---|---:|---:|---|
| Full year 2026 Revenue | $1.741B - $1.761B | $1.685B - $1.725B | +$56M - $36M |
| Full year 2026 Center Margin | $599M - $613M | $570M - $594M | +$29M - $19M |
| Full year 2026 Adjusted EBITDA | $242M - $250M | $215M - $235M | +$27M - $15M |
| Q4 2026 Revenue | $446M - $466M | — | — |
| Q4 2026 Center Margin | $149M - $163M | — | — |
| Q4 2026 Adjusted EBITDA | $56M - $64M | — | — |

## What drove it

- Revenue story: Revenue grew 25% to $455.9 million, driven by higher visit volumes, net clinician growth, improved clinician productivity, and higher total revenue per visit.
- EPS story: Net income of $22.4 million was driven by higher revenue and improved operating leverage, with a tax rate of 22.4%.
- One-off check: Loss on remeasurement of contingent consideration ($2.3M) and transaction costs ($0.5M) are one-time items.

## The good

- Revenue growth of 25% YoY
- Adjusted EBITDA of $68.4 million (+70% YoY)
- Center Margin of $161.4 million (+38% YoY)
- Raised full year 2026 guidance across all metrics

## The bad

- Free Cash Flow of $22.4 million, down from $87.9 million in Q2 2026
- Cash and cash equivalents decreased to $218.8 million

## The ugly

- none

## Open questions

- The reconciliation for forward-looking Q4 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not provided.
- The release does not disclose the specific revenue mix by geography or specialty.

## Full release

### LifeStance Health Group (LFST) earnings release, November 5, 2026

LifeStance Health Group, Inc. (LFST) · Form 8-K, Item 2.02 · Filed 2026-11-05 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1845257/000119312526447943/)

Investor Relations Contact

Monica Prokocki

VP of Finance & Investor Relations

602-767-2100 investor.relations@lifestance.com

LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook

SCOTTSDALE, Ariz. – November 5, 2026 – LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2026.

(All results compared to prior-year comparative period, unless otherwise noted)

Q3 2026 Highlights and FY 2026 Outlook

• Revenue of $455.9 million increased 25% compared to revenue of $363.8 million

• Clinician base increased 11% to 8,863 clinicians, a sequential net increase of 321 in the third quarter

• Third quarter visit volumes increased 17% to 2.7 million

• Net income of $22.4 million compared to net income of $1.1 million

• Adjusted EBITDA of $68.4 million compared to Adjusted EBITDA of $40.2 million

• Net cash provided by operations of $37.0 million in the third quarter

• Free Cash Flow generation of $22.4 million in the third quarter

• For full year 2026, raising revenue expectations to $1.741 billion to $1.761 billion, Center Margin expectations to $599 million to $613 million, and Adjusted EBITDA expectations to $242 million to $250 million

“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations,” said Dave Bourdon, CEO of LifeStance. “The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence. At the same time, the investments we are making in our platform, including the implementation of our new EHR, are positioning LifeStance for continued success and scale over the long term.”

NM - not meaningful

(All results compared to prior-year period, unless otherwise noted)

• Revenue grew 25% to $455.9 million. Revenue growth in the third quarter was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.

• i ncome from operations was $33.1 million and net income was $22.4 million.

• Center Margin grew 38% to $161.4 million, or 35.4% of total revenue.

• Adjusted EBITDA increased 70% to $68.4 million, or 15.0% of total revenue. Adjusted EBITDA as a percentage of revenue increased in the third quarter as a result of higher total revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses.

Balance Sheet, Cash Flow, and Capital Allocation

For the nine months ended September 30, 2026, LifeStance generated $170.0 million of cash flow from operations, including $37.0 million during the third quarter of 2026. The Company ended the third quarter with cash and cash equivalents of $218.8 million and net long-term debt of $255.5 million.

2026 Guidance

LifeStance is providing the following outlook for 2026:

• The Company is raising full year revenue to $1.741 billion to $1.761 billion, Center Margin to $599 million to $613 million, and Adjusted EBITDA to $242 million to $250 million.

• For the fourth quarter of 2026, the Company expects total revenue of $446 million to $466 million, Center Margin of $149 million to $163 million, and Adjusted EBITDA of $56 million to $64 million.

Conference Call, Webcast Information, and Presentations

LifeStance will hold a conference call today, November 5, 2026 at 8:30 a.m. Eastern Time to discuss the third quarter 2026 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 3056663 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.

About LifeStance Health Group, Inc.

Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation’s largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ over 8,800 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 35 states and more than 575 centers. To learn more, please visit www.LifeStance.com.

We routinely post information that may be important to investors on the “Investor Relations” section of our website at investor.lifestance.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Forward-Looking Statements... (truncated)essions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates paid by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be materially harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial performance would be harmed; the impact on us of healthcare reform legislation and other changes in the healthcare industry and in healthcare spending is currently unknown, but may harm our business; if our or our vendors’ security measures fail or are breached and unauthorized access to our employees’, patients’ or partners’ data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under “Risk Factors” included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2025 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.

Non-GAAP Financial Information

This press release contains certain non-GAAP financial measures, including Center Margin, Adjusted EBITDA, and Adjusted EBITDA margin. Tables showing the reconciliation of these non-GAAP financial measures to the comparable GAAP measures are included at the end of this release. Management believes these non-GAAP financial measures are useful in evaluating the Company’s operating performance, and may be helpful to securities analysts, institutional investors and other interested parties in understanding the Company’s operating performance and prospects. This press release also refers to Free Cash Flow, which is calculated as net cash provided by operating activities less purchases of property and equipment. Management believes Free Cash Flow is a useful indicator of liquidity that provides information to management and investors about the amount of cash generated from our operations that, after investments in property and equipment, can be used for future growth. These non-GAAP financial measures, as calculated, may not be comparable to companies in other industries or within the same industry with similarly titled measures of performance. Therefore, the Company’s non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP, such as net income (loss) or income from operations.

Center Margin and Adjusted EBITDA anticipated for the fourth quarter of 2026 and full year 2026 are calculated in a manner consistent with the historical presentation of these measures at the end of this release. Reconciliation for the forward-looking fourth quarter of 2026 and full year 2026 Center Margin, Adjusted EBITDA guidance and Free Cash Flow is not being provided, as LifeStance does not currently have sufficient data to accurately estimate the variables and individual adjustments for such reconciliation. As such, LifeStance management cannot estimate on a forward-looking basis without unreasonable effort the impact these variables and individual adjustments will have on its reported results.

Management acknowledges that there are many items that impact a company’s reported results and the adjustments reflected in these non-GAAP measures are not intended to present all items that may have impacted these results.

### # # #

#### Financial statements

##### Income Statement (Three Months Ended September 30, — (In thousands, except per share amounts))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| TOTAL REVENUE | 455,864 | 363,809 | 1,294,694 | 1,042,090 |
| **OPERATING EXPENSES** | | | | |
| Center costs, excluding depreciation and amortization shown separately below | 294,462 | 247,227 | 844,319 | 707,286 |
| General and administrative expenses | 113,389 | 95,615 | 321,858 | 287,421 |
| Depreciation and amortization | 14,936 | 13,557 | 42,503 | 41,319 |
| Total operating expenses | 422,787 | 356,399 | 1,208,680 | 1,036,026 |
| INCOME FROM OPERATIONS | 33,077 | 7,410 | 86,014 | 6,064 |
| **OTHER EXPENSE** | | | | |
| Loss on remeasurement of contingent consideration | -2,339 |  | -2,370 |  |
| Transaction costs | -510 |  | -1,499 |  |
| Interest expense, net | -2,491 | -2,814 | -6,916 | -8,787 |
| Other expense | -334 | -24 | -609 | -117 |
| Total other expense | -5,674 | -2,838 | -11,394 | -8,904 |
| INCOME (LOSS) BEFORE INCOME TAXES | 27,403 | 4,572 | 74,620 | -2,840 |
| INCOME TAX (PROVISION) BENEFIT | -5,018 | -3,495 | -14,380 | 835 |
| NET INCOME (LOSS) | 22,385 | 1,077 | 60,240 | -2,005 |
| **EARNINGS (LOSS) PER SHARE** | | | | |
| Basic | 0.06 | 0 | 0.16 | -0.01 |
| Diluted | 0.06 | 0 | 0.15 | -0.01 |
| **Weighted-average shares outstanding** | | | | |
| Basic | 381,214 | 386,963 | 383,976 | 385,672 |
| Diluted | 391,223 | 388,895 | 391,180 | 385,672 |
| NET INCOME (LOSS) | 22,385 | 1,077 | 60,240 | -2,005 |
| **OTHER COMPREHENSIVE LOSS** | | | | |
| Unrealized losses on cash flow hedge, net of tax |  | -345 |  | -929 |
| COMPREHENSIVE INCOME (LOSS) | 22,385 | 732 | 60,240 | -2,934 |

##### Income Statement (Three Months Ended September 30, — FROM OPERATIONS TO CENTER MARGIN (in thousands))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Income from operations | 33,077 | 7,410 | 86,014 | 6,064 |
| **Adjusted for:** | | | | |
| Depreciation and amortization | 14,936 | 13,557 | 42,503 | 41,319 |
| General and administrative expenses (1) | 113,389 | 95,615 | 321,858 | 287,421 |
| Center Margin | 161,402 | 116,582 | 450,375 | 334,804 |

##### Income Statement (Three Months Ended September 30, — TO ADJUSTED EBITDA (in thousands))

| | Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|---:|---:|
| Net income (loss) | 22,385 | 1,077 | 60,240 | -2,005 |
| **Adjusted for:** | | | | |
| Interest expense, net | 2,491 | 2,814 | 6,916 | 8,787 |
| Depreciation and amortization | 14,936 | 13,557 | 42,503 | 41,319 |
| Income tax provision (benefit) | 5,018 | 3,495 | 14,380 | -835 |
| Loss on remeasurement of contingent consideration | 2,339 |  | 2,370 |  |
| Stock-based compensation expense | 18,168 | 18,297 | 53,117 | 57,997 |
| Loss on disposal of assets | 334 | 24 | 609 | 117 |
| Transaction costs (1) | 510 |  | 1,499 |  |
| Executive transition costs |  | 577 |  | 1,296 |
| Litigation costs (2) | 34 | -70 | -94 | 1,088 |
| Strategic initiatives (3) | 1,741 |  | 2,738 |  |
| Real estate optimization and restructuring charges (4) | -27 | -6 | -38 | -103 |
| Amortization of cloud-based software implementation costs (5) | 428 | 444 | 1,269 | 1,199 |
| Adjusted EBITDA | 68,357 | 40,209 | 185,509 | 108,860 |

##### Balance Sheet (September 30, 2026 — (In thousands, except for par value))

| | September 30, 2026 | December 31, 2025 |
|---|---:|---:|
| **CURRENT ASSETS** | | |
| Cash and cash equivalents | 218,818 | 248,642 |
| Patient accounts receivable, net | 120,940 | 95,710 |
| Prepaid expenses and other current assets | 37,021 | 71,848 |
| Total current assets | 376,779 | 416,200 |
| **NONCURRENT ASSETS** | | |
| Property and equipment, net | 166,428 | 161,583 |
| Right-of-use assets | 162,395 | 149,720 |
| Intangible assets, net | 170,041 | 177,665 |
| Goodwill | 1,305,389 | 1,293,346 |
| Other noncurrent assets | 5,251 | 5,419 |
| Total noncurrent assets | 1,809,504 | 1,787,733 |
| Total assets | 2,186,283 | 2,203,933 |
| **CURRENT LIABILITIES** | | |
| Accounts payable | 5,502 | 6,122 |
| Accrued payroll expenses | 129,848 | 143,327 |
| Other accrued expenses | 60,099 | 42,187 |
| Operating lease liabilities, current | 45,039 | 45,544 |
| Other current liabilities | 20,641 | 14,782 |
| Total current liabilities | 261,129 | 251,962 |
| **NONCURRENT LIABILITIES** | | |
| Long-term debt, net | 255,524 | 265,927 |
| Operating lease liabilities, noncurrent | 160,458 | 148,553 |
| Deferred tax liability, net | 16,408 | 16,408 |
| Other noncurrent liabilities | 373 | 68 |
| Total noncurrent liabilities | 432,763 | 430,956 |

##### Cash Flow (Nine Months Ended September 30, — (In thousands))

| | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 |
|---|---:|---:|
| **CASH FLOWS FROM OPERATING ACTIVITIES** | | |
| Net income (loss) | 60,240 | -2,005 |
| **Adjustments to reconcile net income (loss) to net cash provided by operating activities:** | | |
| Depreciation and amortization | 42,503 | 41,319 |
| Non-cash operating lease costs | 32,694 | 31,265 |
| Stock-based compensation | 53,117 | 57,997 |
| Amortization of discount and debt issue costs | 758 | 762 |
| Other, net | 4,356 | 1,440 |
| **Change in operating assets and liabilities, net of businesses acquired:** | | |
| Patient accounts receivable, net | -24,381 | 10,729 |
| Prepaid expenses and other current assets | 33,546 | -10,410 |
| Accounts payable | -513 | 2,868 |
| Accrued payroll expenses | -14,146 | -3,689 |
| Operating lease liabilities | -34,116 | -35,829 |
| Other accrued expenses | 15,979 | -5,856 |
| Net cash provided by operating activities | 170,037 | 88,591 |
| **CASH FLOWS FROM INVESTING ACTIVITIES** | | |
| Purchases of property and equipment | -37,415 | -25,214 |
| Acquisitions of businesses, net of cash acquired | -9,590 |  |
| Net cash used in investing activities | -47,005 | -25,214 |
| **CASH FLOWS FROM FINANCING ACTIVITIES** | | |
| Payments of long-term debt | -10,875 | -5,438 |
| Taxes related to net share settlement of equity awards | -24,919 | -8,607 |
| Proceeds from the exercise of stock options | 5,368 |  |
| Repurchases of common stock | -122,430 |  |
| Net cash used in financing activities | -152,856 | -14,045 |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | -29,824 | 49,332 |
| Cash and cash equivalents - beginning of period | 248,642 | 154,571 |
| CASH AND CASH EQUIVALENTS – END OF PERIOD | 218,818 | 203,903 |
| **SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION** | | |
| Cash paid for interest, net | 12,298 | 13,253 |
| Cash paid for taxes, net of refunds | 1,294 | 1,564 |
| **SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES** | | |
| Contingent consideration incurred in acquisitions of businesses | 3,983 | $— |
| Acquisition of property and equipment included in liabilities | 4,546 | 4,484 |

##### Income Statement (in millions)

| | Q3 2026 | Q3 2025 | Y/Y |
|---|---:|---:|---:|
| **(in millions)** | | | |
| Total revenue | 455.9 | 363.8 | 25.0% |
| Income from operations | 33.1 | 7.4 |  |
| Center Margin | 161.4 | 116.6 | 38.0% |
| Net income | 22.4 | 1.1 |  |
| Adjusted EBITDA | 68.4 | 40.2 | 70.0% |
| **As % of Total revenue:** | | | |
| Income from operations | 7.3 | 2 |  |
| Center Margin | 35.4 | 32 |  |
| Net income | 4.9 | 0.3 |  |
| Adjusted EBITDA | 15 | 11.1 |  |
